Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR)
Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR)
Sponsor: Hospital Universitari Vall d'Hebron Research Institute
This PHASE3 trial investigates Bicuspid Aortic Valve and is currently completed. Hospital Universitari Vall d'Hebron Research Institute leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jan 2021 — Mar 2021 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Mar 2018 [monthly]
Recruiting PHASE3
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hospital Universitari Vall d'Hebron Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .